Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 70Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Rectal Neoplasms 13Colonic Neoplasms 13Neoplasm Metastasis 12Esophageal Neoplasms 11Neoplasms 9Gallbladder Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Bile Duct Neoplasms 7Liver Neoplasms 6Adenocarcinoma Of Esophagus 5Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Gastrointestinal Neoplasms 3Esthesioneuroblastoma, Olfactory 3Esophageal Squamous Cell Carcinoma 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Pancreatic Intraductal Neoplasms 2Lung Neoplasms 2Gastrointestinal Stromal Tumors 2Carcinoma, Renal Cell 2Biliary Tract Neoplasms 2Anus Neoplasms 2Adenomatous Polyposis Coli 2

Interventions

pembrolizumab 13Gemcitabine 12Cyclophosphamide 10Carboplatin 10Specimen Handling 8Magnetic Resonance Spectroscopy 8Cisplatin 8Docetaxel 7X-Rays 6Filgrastim 6Doxorubicin 6Biopsy 6tislelizumab 5Radiosurgery 5Phantoms, Imaging 5Paclitaxel 5Nivolumab 5Irinotecan 5Bevacizumab 5130-nm albumin-bound paclitaxel 5spartalizumab 4palbociclib 4Thiotepa 4Temozolomide 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Mesna 4Ipilimumab 4Imatinib Mesylate 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Erlotinib Hydrochloride × Gastrointestinal × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡